| GCHFR — GTP Cyclohydrolase I Feedback Regulator | |
|---|---|
| Symbol | GCHFR |
| Full Name | GTP Cyclohydrolase I Feedback Regulator |
| Chromosome | 9q34.3 |
| NCBI Gene | [2650](https://www.ncbi.nlm.nih.gov/gene/2650) |
| OMIM | [602200](https://www.omim.org/entry/602200) |
| Ensembl | [ENSG00000108468](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000108468) |
| UniProt | [Q8WY44](https://www.uniprot.org/uniprot/Q8WY44) |
| Protein Length | 83 amino acids |
| Molecular Weight | ~9.5 kDa |
| Expression | Brain (substantia nigra, striatum), liver, adrenal gland |
GCHFR encodes the GTP cyclohydrolase I feedback regulator, a small protein that negatively regulates the first and rate-limiting step in tetrahydrobiopterin (BH4) biosynthesis. BH4 is an essential cofactor for several critical enzymatic reactions, including phenylalanine hydroxylase, tyrosine hydroxylase, and tryptophan hydroxylase—enzymes required for neurotransmitter synthesis. The gene is located on chromosome 9q34.3 and encodes a protein of only 83 amino acids, making it one of the smallest known regulatory proteins[1].
The GCHFR protein acts as a feedback inhibitor, responding to BH4 levels to modulate the rate of BH4 production. This regulatory mechanism is crucial for maintaining appropriate BH4 concentrations in tissues, particularly in the brain where BH4 is essential for dopamine and serotonin synthesis[2].
Tetrahydrobiopterin (BH4) is synthesized through a multi-step pathway:
GCH1 is the rate-limiting enzyme in this pathway. GCHFR directly inhibits GCH1 activity, providing feedback regulation[3].
GCHFR regulates GCH1 through several mechanisms:
The feedback loop ensures BH4 production matches cellular needs without excessive accumulation.
BH4 is an essential cofactor for:
| Enzyme | Function | Product |
|---|---|---|
| Phenylalanine hydroxylase | Converts phenylalanine to tyrosine | Tyrosine |
| Tyrosine hydroxylase | Converts tyrosine to L-DOPA | L-DOPA (rate-limiting for dopamine) |
| Tryptophan hydroxylase | Converts tryptophan to 5-HTP | Serotonin precursor |
| Nitric oxide synthase | Produces nitric oxide | NO |
These reactions are critical for dopamine, serotonin, and other neurotransmitter production[4].
BH4 is an essential cofactor for tyrosine hydroxylase (TH), the rate-limiting enzyme in dopamine biosynthesis. By regulating BH4 levels, GCHFR indirectly influences:
Studies have shown that BH4 levels are reduced in the substantia nigra of Parkinson's disease patients, potentially due to altered GCHFR regulation[5][6].
Similarly, tryptophan hydroxylase (TPH), the rate-limiting enzyme in serotonin synthesis, requires BH4 as a cofactor. GCHFR-mediated BH4 regulation therefore affects:
BH4 is also required for all three nitric oxide synthase (NOS) isoforms (nNOS, eNOS, iNOS). Proper BH4 levels are essential for:
Dysregulated BH4 metabolism can lead to NOS uncoupling, producing superoxide rather than NO, contributing to oxidative stress in neurodegeneration[7].
GCHFR's role in BH4 production directly connects to Parkinson's disease:
Therapeutic strategies include BH4 supplementation to support dopamine production[8].
Evidence suggests GCHFR and BH4 are relevant to Alzheimer's disease:
Amyloid-β metabolism: BH4 can influence amyloid precursor protein (APP) processing. Proper BH4 regulation may therefore affect amyloid-β production and clearance[9].
Tau phosphorylation: BH4 levels may influence tau pathology through effects on kinase/phosphatase balance.
Vascular function: BH4 is critical for endothelial function and cerebral blood flow. Dysregulated BH4 could contribute to vascular aspects of AD.
Oxidative stress: As an antioxidant, BH4 helps neutralize reactive oxygen species. Reduced BH4 may contribute to the oxidative stress observed in AD brains.
Schizophrenia: BH4 metabolism is altered in schizophrenia, and GCHFR variants may affect dopamine and serotonin synthesis relevant to this disorder[11][12].
Depression: Serotonin biosynthesis requires BH4, making GCHFR regulation relevant to depressive disorders.
GCHFR is expressed in:
BH4 supplementation has been explored in various neurological conditions:
Modulating GCHFR activity could provide therapeutic benefits:
Key approaches for studying GCHFR include:
NCBI Gene - GCHFR. NCBI. 2024. ↩︎
Maita N, et al. Structure of GTP cyclohydrolase I feedback regulator. Journal of Biological Chemistry. 2002. ↩︎
Kuster A, et al. GTP cyclohydrolase I regulation and function. Current Drug Metabolism. 2013. ↩︎
Thony B, et al. Tetrahydrobiopterin in brain function and disease. Journal of Neural Transmission. 1998. ↩︎
Foubert C, et al. BH4 and Parkinson's disease. Journal of Parkinson's Disease. 2008. ↩︎
Sun J, et al. GTP cyclohydrolase I in dopaminergic neuroprotection. Journal of Neuroscience Research. 2005. ↩︎
Wachter R, et al. Tetrahydrobiopterin and nitric oxide synthase in neurodegenerative diseases. Free Radical Biology and Medicine. 2010. ↩︎
Nagatsu T, et al. BH4 and neurotransmitter synthesis in Parkinson's disease. Neurobiology of Disease. 2010. ↩︎
Anderson FL, et al. BH4 and Alzheimer's disease. Journal of Alzheimer's Disease. 2012. ↩︎
Ichinose H, et al. GTP cyclohydrolase I deficiency and dystonia. Movement Disorders. 2019. ↩︎
Goodman L, et al. Tetrahydrobiopterin in psychiatric disorders. Journal of Psychiatry Neuroscience. 2007. ↩︎
Katus L, et al. GTPCH and BH4 in psychiatric disease. Journal of Molecular Neuroscience. 2013. ↩︎